AAIC 2025 Abstract·25 DecA randomized, double‐blind, placebo‐controlled phase 2 study of SHR‐1707, an anti‐amyloid‐β antibody, in patients with mild cognitive impairment and mild Alzheimer's diseaseTrial in peopleInterventionsPaper